Assertio Holdings Inc (ASRT)Healthcare | Drug Manufacturers - Specialty & Generic | Lake Forest, United States |
USD
|
Hot Take ↕ | Aug. 22, 2026, 9:58 a.m. UTC
The investment thesis here is entirely event-driven and binary. In the short term, the stock is a high-conviction momentum play priced for a specific outcome: the completion of the Zydus Worldwide acquisition at $23.50 per share. With the deal announced and the stock trading precisely at that target price, the immediate catalyst is the regulatory approval and closing of the merger, which offers a guaranteed 0% return if the price holds, or significant upside if the market prices in a premium for the certainty of the exit. However, looking beyond this transaction, the underlying business is fundamentally broken. The company is reporting a massive contraction in revenue of nearly 63%, negative operating margins, and negative returns on equity. The balance sheet shows deteriorating fundamentals with negative free cash flow from operations. There is no long-term growth story or sustainable competitive advantage left in the core business; the value exists solely in the acquisition premium. Furthermore, there is no dividend income to provide any cushion during the waiting period for the deal to close. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 53.302 |
| Revenue per Share | 15.92 |
| Market Cap | 151,861,232 |
| Forward P/E | 9.11 |
| Beta | 0.53 |
| Profit Margins | -34.94% |
| Website | https://www.assertiotx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.406924 |
| Address1 | 100 South Saunders Road |
| Address2 | Suite 300 |
| All Time High | 2,024.4 |
| All Time Low | 7.705499 |
| Ask | 23.5 |
| Ask Size | 100 |
| Audit Risk | 3 |
| Average Daily Volume10 Day | 117,665 |
| Average Volume | 322,528 |
| Average Volume10Days | 117,665 |
| Beta | 0.531 |
| Bid | 20.19 |
| Bid Size | 100 |
| Board Risk | 3 |
| Book Value | 11.735 |
| City | Lake Forest |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Currency | USD |
| Current Price | 23.5 |
| Current Ratio | 1.822 |
| Date Short Interest | 1,780,012,800 |
| Day High | 23.5 |
| Day Low | 23.48 |
| Debt To Equity | 53.302 |
| Ebitda | 3,827,000 |
| Ebitda Margins | 0.03746 |
| Enterprise To Ebitda | 31.514 |
| Enterprise To Revenue | 1.181 |
| Enterprise Value | 120,605,232 |
| Exchange | NGM |
| Exchange Timezone Name | UTC |
| Fax | 510 744 8001 |
| Fifty Day Average | 21.9949 |
| Fifty Two Week High | 23.5 |
| Fifty Two Week Low | 8.61 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,781,616,600 |
| Float Shares | 6,264,825 |
| Forward Eps | 2.58 |
| Forward P E | 9.108527 |
| Free Cashflow | 7,750,750 |
| Full Time Employees | 53 |
| Fullday Price | 23.5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,780,531,200 |
| Gross Margins | 0.70332 |
| Gross Profits | 71,850,000 |
| Held Percent Insiders | 0.01968 |
| Held Percent Institutions | 0.29285 |
| Implied Shares Outstanding | 6,462,180 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,766,707,200 |
| Last Split Factor | 1:15 |
| Long Business Summary | Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois. |
| Long Name | Assertio Holdings Inc |
| Market Cap | 151,861,232 |
| Max Age | 86,400 |
| Message Board Id | finmb_363049 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -35,690,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Number Of Analyst Opinions | 3 |
| Open | 23.48 |
| Operating Cashflow | -7,081,000 |
| Operating Margins | -1.85946 |
| Overall Risk | 1 |
| Peg Ratio | 0.89 |
| Phone | 224 419 7106 |
| Previous Close | 0.0 |
| Price Hint | 2 |
| Price To Book | 2.0025566 |
| Price To Sales Trailing12 Months | 1.4865329 |
| Profit Margins | -0.34936002 |
| Quick Ratio | 1.453 |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.33333 |
| Regular Market Day High | 23.5 |
| Regular Market Day Low | 23.48 |
| Regular Market Open | 23.48 |
| Regular Market Previous Close | 0.0 |
| Regular Market Volume | 269,201 |
| Return On Assets | -0.057129998 |
| Return On Equity | -0.38759 |
| Revenue Growth | -0.625 |
| Revenue Per Share | 15.92 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 6,462,180 |
| Shares Percent Shares Out | 0.051799998 |
| Shares Short | 334,922 |
| Shares Short Previous Month Date | 1,777,507,200 |
| Shares Short Prior Month | 289,282 |
| Short Name | Assertio Holdings, Inc. |
| Short Percent Of Float | 0.0525 |
| Short Ratio | 0.71 |
| State | IL |
| Symbol | ASRT |
| Target High Price | 28.0 |
| Target Low Price | 21.8 |
| Target Mean Price | 24.43333 |
| Target Median Price | 23.5 |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 71,569,000 |
| Total Cash Per Share | 11.075 |
| Total Debt | 40,313,000 |
| Total Revenue | 102,158,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | -5.55 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 14.897315 |
| Underlying Symbol | ASRT |
| Uuid | b0b71d5e-e500-3f56-bb27-7703d923929a |
| Volume | 269,201 |
| Website | https://www.assertiotx.com |
| Zip | 60,045 |